These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 20686367)

  • 1. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.
    Young E; Miele L; Tucker KB; Huang M; Wells J; Gu JW
    Cancer Biol Ther; 2010 Oct; 10(7):703-11. PubMed ID: 20686367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
    Gu JW; Young E; Busby B; Covington J; Johnson JW
    Cancer Biol Ther; 2009 Mar; 8(6):514-21. PubMed ID: 19242105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the anticancer mechanisms of sunitinib.
    Pal SK; Figlin RA; Yu H
    Cancer Biol Ther; 2010 Oct; 10(7):712-4. PubMed ID: 20716960
    [No Abstract]   [Full Text] [Related]  

  • 4. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
    Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
    Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
    Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice.
    Gu JW; Young E; Patterson SG; Makey KL; Wells J; Huang M; Tucker KB; Miele L
    Cancer Biol Ther; 2011 May; 11(10):910-7. PubMed ID: 21451264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
    Abrams TJ; Murray LJ; Pesenti E; Holway VW; Colombo T; Lee LB; Cherrington JM; Pryer NK
    Mol Cancer Ther; 2003 Oct; 2(10):1011-21. PubMed ID: 14578466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
    Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
    Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
    Schueneman AJ; Himmelfarb E; Geng L; Tan J; Donnelly E; Mendel D; McMahon G; Hallahan DE
    Cancer Res; 2003 Jul; 63(14):4009-16. PubMed ID: 12873999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
    Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.
    Lee TH; Seng S; Sekine M; Hinton C; Fu Y; Avraham HK; Avraham S
    PLoS Med; 2007 Jun; 4(6):e186. PubMed ID: 17550303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.
    Syed Khaja AS; Dizeyi N; Kopparapu PK; Anagnostaki L; Härkönen P; Persson JL
    PLoS One; 2013; 8(8):e72210. PubMed ID: 23991063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
    Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.